Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01817530 |
Recruitment Status
:
Completed
First Posted
: March 25, 2013
Last Update Posted
: February 2, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Heavy Uterine Bleeding Uterine Fibroids | Other: Placebo Drug: Elagolix Drug: Estradiol/norethindrone acetate, E2/NETA Drug: Estradiol/norethindrone acetate, E2/NETA Dose 2 Drug: Estradiol/norethindrone acetate | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 571 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids |
Actual Study Start Date : | April 8, 2013 |
Actual Primary Completion Date : | June 2015 |
Actual Study Completion Date : | December 2015 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo 1
Placebo
|
Other: Placebo
Placebo for 6 Month Treatment Period
|
Experimental: Elagolix Dose 1
Elagolix Dose 1
|
Drug: Elagolix
Elagolix Dose 1 for 6 Month treatment Period
Other Name: ABT-620
|
Experimental: Elagolix Dose 1 plus E2/NETA Dose 1
Elagolix Dose 1 plus E2/NETA (estradiol/norethindrone acetate) Dose 1
|
Drug: Elagolix
Elagolix Dose 1 for 6 Month treatment Period
Other Name: ABT-620
Drug: Estradiol/norethindrone acetate, E2/NETA
E2/NETA Dose 1
|
Experimental: Elagolix Dose 1 plus E2/NETA Dose 2
Elagolix Dose 1 plus E2/NETA (estradiol/norethindrone acetate) Dose 2
|
Drug: Elagolix
Elagolix Dose 1 for 6 Month treatment Period
Other Name: ABT-620
Drug: Estradiol/norethindrone acetate, E2/NETA Dose 2
E2/NETA Dose 2
|
Placebo Comparator: Placebo 2
Placebo
|
Other: Placebo
Placebo for 6 Month Treatment Period
|
Experimental: Elagolix Dose 2
Ealgolix Dose 2
|
Drug: Elagolix
Elagolix Dose 2 for 6 Month Treatment Period
Other Name: ABT-620
|
Experimental: Elagolix Dose 2 plus E2/NETA Dose 1
Elagolix Dose 2 plus E2/NETA (estradiol/norethindrone acetate) Dose 1
|
Drug: Estradiol/norethindrone acetate, E2/NETA
E2/NETA Dose 1
|
Experimental: Elagolix Dose 2 plus E2/NETA Dose 2
Elagolix Dose 2 plus E2/NETA (estradiol/norethindrone acetate) Dose 2
|
Drug: Estradiol/norethindrone acetate
E2/NETA Dose 2
|
- Change in Menstrual Blood Loss [ Time Frame: From Baseline to Month 6 ]Change in menstrual blood loss measured by alkaline hematin method
- Change in Physical Examination [ Time Frame: From Day 1 through 6 Months Post-dosing ]
- Change from Baseline in the number of subjects with adverse events [ Time Frame: From Day 1 through 6 months post dose ]
- Change in Bone Mineral Density (BMD) [ Time Frame: From Day 1 through Month 6 ]
- Change in Endometrial Assessment [ Time Frame: From 3 months prior to dosing up to 6 Months Post-dosing ]Change in endometrial thickness
- Change in Clinical Laboratory Tests [ Time Frame: From Day 1 up to 3 Months Post-dosing ]Chemistry, Urinalysis, complete blood count, bone biomarkers, lipid profile
- Percentage of Subjects with reduction in Menstrual Blood Loss [ Time Frame: Up to Month 6 ]
- Percentage Subjects with amenorrhea [ Time Frame: Up to Month 6 ]
- Percentage of Subjects with No Bleeding (spotting allowed) [ Time Frame: Up to Month 6 ]
- Number of Bleeding Days [ Time Frame: Up to Month 6 ]
- Percent Change from baseline in bleeding scores per bleeding diary [ Time Frame: From Day 1 to Month 6 ]
- Percent Change in Uterine Volume [ Time Frame: From Day 1 to Month 6 ]
- Percent Change in Fibroid Volume [ Time Frame: From Day 1 to Month 6 ]
- Percent change in hemoglobin concentration [ Time Frame: From Day 1 through Month 6 ]
- Change in bone mineral density [ Time Frame: From 3 months prior to dosing through 6 months post-dosing ]
- Change in percentage of subjects with hypoestrogenic effects [ Time Frame: From Day 1 to Month 6 ]
- Proportion reporting treatment-emergent adverse events [ Time Frame: Up to 6 months post-dosing ]
- Change from Baseline in the percent of subjects with adverse events [ Time Frame: From Day 1 through 6 months post dose ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 51 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: - Subject is pre-menopausal female 18 to 51 years of age at Screening.
- Subject has diagnosis of uterine fibroids documented by a Pelvic Ultrasound.
- Subject has heavy uterine bleeding associated with uterine fibroids. Exclusion Criteria: - Subject has had a myomectomy, uterine artery embolization or high intensity focused ultrasound for fibroid destruction within 6 months prior to Screening or endometrial ablation within 5 years prior to Screening.
- Subject has a history of osteoporosis or other metabolic bone disease.
- Subject shows evidence of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric (including depression, schizophrenia, bipolar disorder), or neurologic diseases or any uncontrolled medical illness such as uncontrolled type 2 diabetes. Subject has any history of attempted suicide.
- Subject has a history of clinically significant condition(s) including but not limited to: * Symptomatic Endometriosis * Epilepsy or seizures * Type 1 diabetes * Chronic kidney disease * Any cancer (except treated basal cell carcinoma of the skin), including breast or ovarian cancer or subject has taken any systemic cancer chemotherapy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01817530

Study Director: | Charlotte Owens, MD | AbbVie |
Responsible Party: | AbbVie |
ClinicalTrials.gov Identifier: | NCT01817530 History of Changes |
Other Study ID Numbers: |
M12-813 2013-000082-37 ( EudraCT Number ) |
First Posted: | March 25, 2013 Key Record Dates |
Last Update Posted: | February 2, 2018 |
Last Verified: | January 2018 |
Keywords provided by AbbVie:
Uterine Fibroids Leiomyomata Elagolix Menorrhagia |
Elagolix sodium Heavy Uterine Bleeding ABT-620 |
Additional relevant MeSH terms:
Hemorrhage Leiomyoma Myofibroma Uterine Hemorrhage Menorrhagia Pathologic Processes Neoplasms, Muscle Tissue Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Neoplasms, Connective Tissue Connective Tissue Diseases Uterine Diseases Genital Diseases, Female Menstruation Disturbances |
Estradiol Polyestradiol phosphate Estradiol 3-benzoate Estradiol 17 beta-cypionate Estradiol valerate Norethindrone Norethindrone acetate Estrogens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Contraceptive Agents Reproductive Control Agents Contraceptive Agents, Female Contraceptives, Oral, Synthetic |